18:08 , Dec 7, 2018 |  BC Week In Review  |  Company News

argenx gets $500M up front from Janssen for CD70 mAb

argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) will receive $500 million up front from Janssen Pharmaceuticals Inc. in exchange for exclusive, worldwide rights to anti-CD70 mAb cusatuzumab (ARGX-110). The upfront payment comprises $300 million in cash from the...
00:27 , Dec 4, 2018 |  BC Extra  |  Company News

argenx gets $500M up front from Janssen for CD70 mAb

argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) will receive $500 million up front from Janssen Pharmaceuticals Inc. in exchange for exclusive, worldwide rights to anti-CD70 mAb cusatuzumab (ARGX-110). The upfront payment comprises $300 million in cash from the...
03:50 , Dec 1, 2018 |  BioCentury  |  Product Development

Cell therapy momentum at ASH

This year’s American Society of Hematology (ASH) meeting will showcase a surge in clinical CAR T cell presentations. But gene therapies are not following the same trajectory, despite both modalities being fresh off their first...
19:51 , Nov 2, 2018 |  BC Week In Review  |  Clinical News

argenx's CD70 mAb leads to 92% response rate in AML

In an abstract released ahead of next month’s American Society of Hematology meeting, argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) said cusatuzumab (ARGX-110) plus Vidaza azacitidine led to an overall response rate (ORR) of 92% in the Phase...
19:01 , Nov 1, 2018 |  BC Extra  |  Clinical News

argenx's CD70 mAb leads to 92% response rate in AML

In an abstract released ahead of next month’s American Society of Hematology meeting, argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) said cusatuzumab (ARGX-110) plus Vidaza azacitidine led to an overall response rate (ORR) of 92% in the Phase...
02:15 , Dec 16, 2017 |  BioCentury  |  Product Development

Assessing the BCMA scene

Differences in patient populations and a dearth of clinical outcome data mean it’s too soon to declare bluebird bio Inc.’s anti-BCMA chimeric antigen receptor therapy the leader of the pack of CARs that presented clinical...
16:38 , Dec 15, 2017 |  BC Week In Review  |  Financial News

argenx raises $231M in follow-on

Antibody company argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) raised $231 million through the sale of 4.4 million ADSs at $52 in a bumped-up follow-on underwritten by Cowen, Piper Jaffray, JMP Securities and Wedbush PacGrow. The price is...
03:48 , Dec 15, 2017 |  BC Week In Review  |  Clinical News

argenx reports Phase I/II cancer data of CD70 mAb

argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) reported data from two Phase I/II trials of ARGX-110 at the American Society of Hematology (ASH) meeting in Atlanta. Preliminary data from six evaluable patients with newly diagnosed acute myelogenous leukemia...
21:12 , Dec 14, 2017 |  BC Extra  |  Financial News

argenx, Proteostasis, Dicerna raise follow-ons

Antibody company argenx S.E. (Euronext:ARGX; NASDAQ:ARGX), respiratory company Proteostasis Therapeutics Inc. (NASDAQ:PTI) and RNA therapeutics play Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) raised a combined $311 million in follow-on offerings. argenx raised $231 million through the sale...
01:11 , Dec 13, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lymphoma; renal cancer Cell culture and mouse studies suggest SIRPA inhibitors could help treat Burkitt's lymphoma and renal cell carcinoma (RCC). In a CD20-positive Burkitt's lymphoma cell line co-cultured with human macrophages, an anti-SIRPA...